IP Library Patent Application 18747522
Patent Application
App. No. 18/747,522

METAL PROTOPORPHYRIN FOR TREATMENT OF BK VIRUS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/747,522
Abstract

The inactivation of BK virus in patients diagnosed with BK virus, those receiving a kidney that is infected or suspected of being infected by BK virus, or in the transplanted kidney before, during, and/or after transplant surgery is described.

Claims (16)

1 - 5 . (canceled)

6 . A method of treating a patient undergoing a kidney transplant surgery comprising before the kidney transplant surgery administering an amount of a first metal protoporphyrin and iron source, and after the transplant surgery administering an amount of a second metal protoporphyrin effective to reduce or eliminate the effects of a BK virus.

7 . The method of claim 6 , wherein the first metal protoporphyrin and second metal protoporphyrin is tin protoporphyrin (SnPP).

8 . The method of claim 6 , wherein the non-enveloped virus is a BK virus.

9 . The method of claim 6 , wherein the metal protoporphyrin is administered at a dose rate ranging from 0.06 to 1.125 mg/kg/day.

10 . The method of claim 6 , wherein the metal protoporphyrin is administered at a daily dose ranging from 5 to 90 mg.

11 . A kidney storage solution comprising a metal protoporphyrin.

12 . The kidney storage solution of claim 11 , further comprising at least one impermeant, and sodium (Na + ) and potassium (K + ) electrolytes.

13 . The kidney storage solution of claim 12 , wherein the impermeant is selected from glucose, lactobionate, mannitol, raffinose, or combinations thereof.

14 . The kidney storage solution of claim 12 , further comprising one or more colloids, additional electrolytes, antioxidants, nutrients, additives, or combinations thereof.

15 . The kidney storage solution of claim 14 , wherein the kidney storage solution comprises at least one colloid, the colloid being selected from hydroxymethyl starch or PEG-35, or combinations thereof.

16 . The kidney storage solution of claim 14 , wherein the kidney storage solution comprises at least one additional electrolyte, the additional electrolyte being selected from calcium (Ca 2+ ), chlorine (Cl − ), sulphate (SO 4 2− ), phosphate (PO 4 3− ), bicarbonate (HCO 3 − ), citrate, or combinations thereof.

17 . The kidney storage solution of claim 14 , wherein the kidney storage solution comprises at least one antioxidant, the antioxidant being selected from allopurinol or glutathione, or combinations thereof.

18 . The kidney storage solution of claim 14 , wherein the kidney storage solution comprises at least one nutrient, the nutrient being selected from tryptophan, adenosine, adenine, glutamic acid, histidine, ketoglutarate, or combinations thereof.

19 . The kidney storage solution of claim 14 , wherein the kidney storage solution comprises at least one additive, the additive being selected from insulin, penicillin, dexamethasone, or combinations thereof.

20 . The kidney storage solution of claim 11 , wherein the osmolarity of the kidney storage solution ranges from 300-500 mOsm/L, and the pH ranges from 7.0 to 7.5.

Assignments (2)
SECURITY INTEREST Recorded Jun 4, 2026
From: RENIBUS THERAPEUTICS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND II, L.P.
Reel/Frame 074858/0020 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2024
From: KEYSER, DONALD JEFFREY; GUILLEM, ALVARO F.; SINGH, BHUPINDER; RUIZ, STACEY
To: RENIBUS THERAPEUTICS, INC.
Reel/Frame 067766/0920 →